Core Viewpoint - The event held in Yinchuan showcased approximately 2,500 technological achievements selected from various universities, research institutions, medical organizations, and enterprises across the country, aiming to enhance the health supply quality and efficiency in Ningxia [1][2]. Group 1: Event Overview - The event was organized by the Ningxia Hui Autonomous Region Health Commission and the Ningxia Hui Autonomous Region Science and Technology Department [1]. - Significant collaborations were established between local innovative entities and institutions such as Zhejiang University and Shanghai University of Traditional Chinese Medicine [1]. - Twelve major technology cooperation projects were signed on-site, including innovations in digital therapy for chronic respiratory diseases and rapid diagnostic technologies for blood infection pathogens [1]. Group 2: Strategic Initiatives - The Ningxia Science and Technology Department has established cooperative relationships with 22 provinces and cities, as well as 67 pharmaceutical universities, research institutions, and medical organizations [1]. - The initiative aims to bridge the gap in medical resources and enhance the quality of health supply through comprehensive innovation [1]. - Future efforts will focus on transforming cooperation intentions into tangible outcomes to support the high-quality development of the life and health industry in Ningxia [2].

证券代码：603658 证券简称：安图生物 公告编号：2025-058 郑州安图生物工程股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会 2020 年 9 月 1 日出具的《关于核准郑州安图生物工 程股份有限公司非公开发行股票的批复》（证监许可【2020】2079 号）核准，郑州 安图生物工程股份有限公司（以下简称"安图生物"或"公司"）向 10 名认购对象非公 开发行人民币普通股（A 股）20,375,760 股，每股面值 1.00 元，每股发行价格为 151.16 元。 本 次非公 开发 行募集 资 金总额为 人民币 3,079,999,881.60 元， 扣除发行费用 本次非公开发行的募集资金已全部到位，上述募集资金经中勤万信会计师事务所(特 殊普通合伙)验证，并由其出具了勤信验字【2020】第0063号验资报告。 二、募集资金专户已开设情况 公司第三届董事会第十九次会议审议通过《关于开设非公开发行股票募集资金 专项账户并签署监管协议的议案》，同意公司根据本次非公开发行股票工作的进展 与非公开发行股票募集资金专项账户存储银行、保荐机构招商证券股份有限公司及 公司子公司安图实验仪器（郑州）有限 ...

郑州安图生物工程股份有限公司 关于增加募集资金专项账户并签订监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会 2020 年 9 月 1 日出具的《关于核准郑州安图生物工 程股份有限公司非公开发行股票的批复》（证监许可【2020】2079 号）核准，郑州 安图生物工程股份有限公司（以下简称"安图生物"或"公司"）向 10 名认购对象非公 开发行人民币普通股（A 股）20,375,760 股，每股面值 1.00 元，每股发行价格为 151.16 元。 本次非公开发行募集资金总额为人民币3,079,999,881.60元，扣除发行费用 28,264,504.42元（不含税），募集资金净额为3,051,735,377.18元。2020年11月3日， 本次非公开发行的募集资金已全部到位，上述募集资金经中勤万信会计师事务所(特 殊普通合伙)验证，并由其出具了勤信验字【2020】第0063号验资报告。 二、募集资金专户已开设情况 公司第三届董事会第十九次会议审议通过《关于开设非公 ...

| 证券代码：603658 证券简称：安图生物 公告编号：2025-057 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 郑州安图生物工程股份有限公司 | | | | | | | | | 关于获得医疗器械注册证的公告 | | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | | | | | 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近 | | | | | | | | | 日收到河南省药品监督管理局颁发的医疗器械注册证，具体如下： | | | | | | | | | 一、医疗器械注册证的具体情况 | | | | | | | | | 注册证 | | | | | | | | | 产品名称 注册证编号 预期用途 | 编号 | | | | | | | | 有效期 | | | | | | | | | IgE 总 检测试剂盒（磁微 本产品用于定量检测 ...

Group 1: Company Performance - Ningde Times reported a net profit of 30.5 billion yuan for the first half of the year, representing a year-on-year increase of 33.02% [1] - The company achieved revenue of 178.9 billion yuan, an increase of 7.27% compared to the same period last year [1] - Gross profit reached 44.8 billion yuan, up 14.45% year-on-year, with a gross margin of 25.02%, an increase of 1.57 percentage points from the previous year [1] Group 2: Stock Trading and Suspensions - Shangwei New Materials announced a suspension of trading due to multiple instances of abnormal stock price fluctuations, with the suspension expected to last no more than three trading days [2] - Jinchengzi is planning to acquire 55% of Samit Optoelectronics, leading to a stock suspension for up to ten trading days [3] - Sanchao New Materials is also planning a change in control, resulting in a stock suspension for up to two trading days [6] - Hehua Co. announced a stock suspension due to potential changes in its controlling shareholder [9] Group 3: Major Investments and Projects - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [5] - The company will use its own funds for this investment, with the final amount to be confirmed based on state-approved preliminary design estimates [5] Group 4: Other Corporate Actions - Sunshine Dairy's controlling shareholder sold a total of 1.1452 million shares, accounting for 0.41% of the company's total share capital, without triggering any significant changes in control [4] - Nanjing Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with uncertainty regarding whether it constitutes a major asset restructuring [7]

Core Insights - Antu Biology has recently received six medical device registration certificates from the Henan Provincial Drug Administration, indicating a significant regulatory approval for its products [1] Product Summary - The registered products include: - Total IgE Test Kit (Magnetic Microparticle Chemiluminescence Method) - β2-Microglobulin Test Kit (Magnetic Microparticle Chemiluminescence Method) - Specific IgE Antibody Calibration Test Kit (Magnetic Microparticle Chemiluminescence Method) - Aldosterone Test Kit (Magnetic Microparticle Chemiluminescence Method) - Dust Mite Allergen-Specific IgE Antibody Test Kit (Magnetic Microparticle Chemiluminescence Method) - Mugwort Allergen-Specific IgE Antibody Test Kit (Magnetic Microparticle Chemiluminescence Method) [1]

郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近 日收到河南省药品监督管理局颁发的医疗器械注册证，具体如下： | 编号 | 产品名称 | 注册证编号 | 注册证 有效期 | 预期用途 | | --- | --- | --- | --- | --- | | 1 | 总 IgE 检测试剂盒（磁微 | 豫械注准 | 5 年 | 本产品用于定量检测人血清/血浆 | | | 粒化学发光法） | 20252400563 | | 中总免疫球蛋白 E（tIgE）的含量。 本产品用于体外定量检测人血清 | | | | | | 或尿液中β 2-微球蛋白（β 2-MG） 的含量。主要用于对肿瘤、多发性 | | | β2-微球蛋白检测试剂盒 | 豫械注准 | | | | 2 | （磁微粒化学发光法） | | 年 5 | 骨髓瘤患者进行动态监测以辅助 | | | | 20252400573 | | 判断疾病进程或治疗效果，不能作 | | | | | | 为恶性肿瘤早期诊断或确诊的依 | | | | | | 据，不用于普通人群的肿瘤筛查。 | | | | | | 本产品为特异性 IgE 抗体校准试 | | | | | ...

| 编号 | 产品名称 | 注册证编号 | 注册证 | 预期用途 | | --- | --- | --- | --- | --- | | | | | 有效期 | | | 1 | 总 IgE 检测试剂盒(磁微 | 酸械注准 | ર 年 | 本产品用于定量检测人血清/血浆 | | | 粒化学发光法) | 20252400563 | | 中总免疫球蛋白 E(tIgE)的含量。 | | | | | | 的含量。主要用于对肿瘤、多发性 | | | | | | 本产品用于体外定量检测人血清 或尿液中B2-微球蛋白(B2-MG) | | | B2-微球蛋白检测试剂盒 | 豫械注准 | | | | 2 | (磁微粒化学发光法) | 20252400573 | ર 年 | 骨髓瘤患者进行动态监测以辅助 判断疾病进程或治疗效果,不能作 | | | | | | 为恶性肿瘤早期诊断或确诊的依 | | | | | | 据,不用于普通人群的肿瘤筛查。 | | | | | | 本产品为特异性 IgE 抗体校准试 | | | | | | 剂盒(sIgE Cal),用于本公司检 | | 3 | 特异性 IgE 抗体校准试剂 | 豫械注准 | ...

安图生物7月30日公告，公司近日收到河南省药品监督管理局颁发的医疗器械注册证，包括总IgE检测试 剂盒、β2-微球蛋白检测试剂盒、特异性IgE抗体校准试剂盒、醛固酮检测试剂盒、粉尘螨过敏原特异性 IgE抗体检测试剂盒和艾蒿过敏原特异性IgE抗体检测试剂盒等。这些注册证的取得丰富了公司产品菜 单，提高产品竞争力，但对短期经营业绩影响较小。产品上市后销售情况取决于市场推广效果，对未来 营业收入的影响尚无法预测。 ...

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 688766 | 普冉股 | 7.79 | 5.03 | 64.60 | 68.94 | 6.72 | | | 份 | | | | | | | 300679 | 电连技 术 | 8.00 | 4.36 | 47.49 | 50.50 | 6.34 | | 300045 | 华力创 | 6.25 | 8.30 | 20.24 | 21.25 | 4.99 | | | 通 | | | | | | | 600238 | *ST椰岛 | 4.93 | 3.25 | 7.03 | 7.23 | 2.85 | | 300761 | 立华股 | 2.54 | 0.92 | 19.35 | 19.79 | 2.29 | | | 份 | | | | | | | 000703 | 恒逸石 化 | 2.13 | 0.30 | 6.09 | 6.22 | 2.09 | | ...